Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3048-3055

  Papaldo, Paola ^b   Ferretti, Gianluigi ^a   Di Cosimo, Serena ^b   Giannarelli, Diana ^b   Marolla, Paolo ^b   Lopez, Massimo ^b   Cortesi, Enrico ^b   Antimi, Mauro ^b   Terzoli, Edmondo ^b   Carlini, Paolo ^b   Vici, Patrizia ^b   Botti, Claudio ^b   Di Lauro, Luigi ^b   Naso, Giuseppe ^b   Nisticò, Cecilia ^b   Mottolese, Marcella ^b   Di Filippo, Franco ^b   Ruggeri, Enzo Maria ^b   Ceribelli, Anna ^b   Cognetti, Francesco ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LONIDAMINE; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG POTENTIATION; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIESIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDAZOLES;

EID: 33746024288     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9488     Document Type: Article

References (28)

1. van Os R, Robinson S, Sheridan T, et al: Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 92:1950-1956, 1998
2. Scinto AF, Cercato MC, Botti C, et al: Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer. Eur J Cancer 30A:1285-1288, 1994
3. Papaldo P, Lopez M, Cortesi E, et al: Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21:3462-3468, 2003
4. Papaldo P, Lopez M, Marolla P, et al: The impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908-6918, 2005
5. De Vita VT: Cancer: Principles and Practice of Oncology (6th ed). Baltimore, MD, Lippincott, Williams, & Wilkins, 2001, pp 426
6. Van Zant G, Goldwasser E: The simultaneous effects of erythropoietin and colony stimulating factor on bone marrow cells. Science 198:733, 1977
7. Souza LM, Boone TC, Gabrilove J, et al: Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232:61-65, 1986
8. Li CL, Johnson GR: Stimulation of multipotential, erythroid and other murine haematopoietic progenitor cells by adherent cell lines in the absence of detectable multi-CSF (IL3). Nature 316:633-636, 1985
9. Metcalf D, Nicola NA: Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol 116:198-206, 1983
10. de Haan G, Loeffler M, Nijhof W: Long-term recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis without causing an anemia. Exp Hematol 20:600-604, 1992
11. Bungart B, Loeffler M, Goris H, et al: Differential effects of recombinant human colony stimulating factor (rh G-CSF) on stem cells in marrow, spleen and peripheral blood in mice. Br J Haematol 76:174-179, 1990
12. Cronkite EP, Burlington H, Shimosaka A, et al: Anemia induced in splenectomized mice by administration of rhG-CSF. Exp Hematol 21:319-325, 1993
13. de Haan G, Engel C, Dontje B, et al: Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration: In vivo interactions and dose-response surfaces. Blood 84:4157-4163, 1994
14. van Os R, Robinson S, Sheridan T, et al: Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal. Stem Cells 18:120-127, 2000
15. Park K, Im T, Sasaki A, et al: Positive effect of granulocyte-colony stimulating factor on erythropoiesis in humans. Osaka City Med J 37:123-132, 1991
16. Miles SA, Mitsuyasu RT, Lee K, et al: Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood 75: 2137-2142, 1990
17. Kojima S, Fukuda M, Miyajima Y, et al: Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 77:937-941, 1991
18. Calhoun DA, Li Y, Christensen RD: Effect of recombinant granulocyte colony-stimulating factor on erythropoiesis in the human fetus and neonate. Pediatr Res 40:872-875, 1996
19. Gabrilove JL, Jakubowski A, Fain K, et al: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454-1461, 1988
20. Fukutani H, Ogawa M, Horikoshi N, et al: Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy-phase I study. Gan To Kagaku Ryoho 16:2005-2012, 1989
21. de Wit R, Verweij J, Bontenbal M, et al: Adverse effect on bone marrow protection of pre-chemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst 88:1393-1398, 1996
22. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
23. Citron ML, Berry DA, Cirrincione C, et al: Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. J Clin Oncol 23:33s, 2005 (abstr 620)
24. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study group 05 randomized trial. J Clin Oncol 19:602-611, 2001
25. Piccart MJ, Di Leo A, Beauduin M, et al.: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
26. Levine MN, Pritchard KI, Bramwell VH, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170, 2005
27. Felici A, Carlini P, Ruggeri EM, et al: A feasibility study of a bi-weekly PELF regimen in advanced gastric cancer. Proc Am Soc Clin Oncol 22:349, 2003 (abstr 1402)
28. Dranitsaris G, Clemons M, Verma S, et al: Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: Development of a prediction model. Lancet Oncol 6:856-863, 2005